BioMed Research International / 2016 / Article / Tab 5 / Clinical Study
Comparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico Table 5 Comparison of our series with other trials.
References Age (M)/ IPI (HSP) Treatment variations Patients (%) OR CR OS PFS/EFS Marchesi et al. 2013 (R) [16 ] (78) 73 32.8% TWCI 36 (49.3%) 91.2% 67.6% 55.5% at 2 yr 47.2% at 2 yr R-CHOP FD 22 (30.1%) — — — — R-CHOP AD 14 (19.1%) — — — — R-CVP CV 37 (50.7%) 69.7% 42.4% 24.3% 21.6% Italiano et al. 2005 (R) [14 ] (83) 29 12.5% CHOP AD 22 (92%) 79% 62.5% 63% at 2 yr 50% at 2 yr Yoshida et al. 2016 (R) [18 ] (72) 135 69% CHOP 46 (34%) 82.6% 76.1% 82.1% at 2 yr 72.5% at 2 yr THP-COP 69 (51%) 81.2% 63.8% 67.6% at 2 yr 64.8% at 2 yr Surgery 3 (2%) — — — — Palliative 17 (13%) — — — — Nabhan et al. 2012 (R) [2 ] (84) 170 62% None 100% 72% 50% 44% at 4 yr 31% at 4 yr Peyrade et al. 2011 (R) [11 ] (83) 149 40% R-CHOP AD 100% 73% 62% 59% at 2 yr 47% at 2 yr Carson et al. 2015 (R) [25 ] (83) 476 11% AT 198 (41%) 28.1 mo WA 87 (18%) 13.1 mo NT 191 (40%) 1.9 mo Kreher et al. 2014 (R) [13 ] (77) 30 27% R-CHOP AD 100% 87% 60% 60% at 3 yr 49% at 3 yr Spina et al. 2012 (P) [26 ] (75) 100 5% Fit (dose at 100%) 83% 54% at 5 yr 84% at 5 yr Fragile (75% reduction) 80% 61% at 5 yr 67% at 5 yr Olivieri et al. 2012 (P) [23 ] (74) 91 29.7% R-CHOP 21 54 (59%) — 81.5% 46% at 5 yr — R-CHOP Doxo liposomal 22 (25%) — 64% 31% — R-mini-CHOP 15 (16%) — 60% 41% — Coiffier et al. 2010 (P) [12 ] (70) 202 15% None 100% 82% 75% 58% at 5 yr 54% at 5 yr Delarue et al. 2013 (P) [24 ] (70) 602 13% R-CHOP-21 (295 pts) 49% 86% 74% 67% at 3 yr 62% at 3 yr 22% R-CHOP 14 (304 pts) 51% — — 72% 60% This series 68 R-CHOP 53 77.3% 66% 74% at 3 yr 70% at 3 yr 75 R-ChOP 48 68.7% 62.5% 60% 54% 77.5 R-COP 40 60% 52.5% 60% 52%
RTX: rituximab, Doxo: doxorubicin, CTX: cyclophosphamide, VCR: Vincristine, PDN: prednisone, AT: treatment with anthracyclines, WA: without anthracyclines, NT: no treatment, FD: full doses, AD: attenuated, CV: conservative, RI: reduced intensity, HSP: high score patients, and TWCI: treatment with curative intention, (R) retrospective and (P) prospective.